Phathom Pharma Upgraded by Barclays to Overweight $18 Target
Barclays lifts Phathom Pharmaceuticals to Overweight with an $18 target, citing a stronger 2026 revenue trajectory an...
Find out the most effective ways to invest money and grow your wealth. Start implementing successful strategies today.
22,287 articlesBarclays lifts Phathom Pharmaceuticals to Overweight with an $18 target, citing a stronger 2026 revenue trajectory an...
NextHome unveils a two-path technology strategy designed for large brokerages, aiming to streamline systems, lower ex...
A federal court clears a $71 million ETH transfer on Arbitrum to Aave, but North Korea-linked creditors retain legal ...
In a market obsessed with the next big disruptor, Republic Services stands out as a reliable, cash-generating machine...
The Senate confirmed Kevin Warsh to lead the Federal Reserve, setting the stage for policy shifts as inflation stays ...
JPMorgan trimmed its price target on Advance Auto Parts to $59 from $64, citing tax stimulus as a partial offset to h...
A Madrid court clears Shakira of a 2011 tax-year fraud claim and orders a 60 million euro refund, including interest....
David Tepper's Appaloosa Management has loaded up on Micron as memory markets rebound, while bets on AMZN and UBER re...
A 68-year-old couple has relied on an 8% yield from a long-held closed-end fund for over a decade, sparking debate am...
Arm stock skyrocketed this week as AI enthusiasm and licensing momentum collided with bullish analyst coverage. This ...
Two US-listed spot HYPE ETFs began trading this month and posted a powerful start, with nine straight days of inflows...
Tensions with Iran push costs beyond official tallies, raising inflation risk and weighing on markets. This report br...